Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

NCT06211114 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Collecting Duct Carcinoma

Interventions

DRUG: PD-(L)1 inhibitor
DRUG: Axitinib

Sponsor

Peking University Cancer Hospital & Institute